Opinion
Video
Author(s):
Hematologist-oncologists address adverse event management and discuss the unmet needs of patients with lower-risk MDS and symptomatic anemia.
Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL
Camidge and Cooper on Finding Purpose and Embracing Nuance in Hospital Chaplaincy
FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD
Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC
Odronextamab Elicits Durable Responses in Heavily Pretreated R/R Follicular Lymphoma
Brentuximab Vedotin Triplet Improves Survival Over R2 Across Key R/R DLBCL Subgroups
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC